• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Equillium Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    5/22/25 5:15:05 PM ET
    $EQ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EQ alert in real time by email
    8-K
    NASDAQ false 0001746466 0001746466 2025-05-21 2025-05-21
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 21, 2025

     

     

    Equillium, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-38692   82-1554746

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2223 Avenida de la Playa  
    Suite 105  
    La Jolla, CA   92037
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (858) 240-1200

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   EQ   The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    (e)

    On May 21, 2025, Equillium, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As described in Item 5.07 of this Current Report on Form 8-K (the “Report”), at the Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan” and the 2018 Plan, as amended, the “2018 Amended Plan”) to, among other things, increase the number of shares of common stock authorized for issuance under the 2018 Plan by 1,781,000 shares. The 2018 Amended Plan was previously approved, subject to stockholder approval, by the Company’s Board of Directors on March 26, 2025. A summary of the principal features of the 2018 Amended Plan are set forth under the heading “Proposal No. 4-Approval of Amendment to the Company’s 2018 Equity Incentive Plan” contained in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 10, 2025, as revised April 30, 2025 (the “2025 Proxy Statement”). The summaries are qualified in their entirety by reference to the 2018 Amended Plan, filed as Exhibit 10.1 to this Report.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    As of April 1, 2025, the record date for the Annual Meeting (the “Record Date”), 35,719,317 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

    A total of 27,708,269 shares of the Company’s common stock were present at the Annual Meeting or represented by proxy, which represents approximately 77.6% of the shares of the Company’s common stock outstanding as of the Record Date.

    Proposal 1. Election of directors.

    The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders and until their respective successor has been duly elected and qualified, or until their earlier death, resignation or removal. The final voting results are as follows:

     

    Name

       Votes For      Votes Withheld      Broker Non-
    Votes
     

    Stephen Connelly, Ph.D.

         20,043,585        787,440        6,877,244  

    Bala S. Manian, Ph.D.

         19,222,114        1,608,911        6,877,244  

    Barbara Troupin, M.D.

         19,832,391        998,634        6,877,244  

    Proposal 2. Approval of an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split.

    The Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s common stock at a ratio in the range of 1-for-2 to 1-for-20, inclusive, with such ratio to be determined in the discretion of the Company’s Board of Directors and with such reverse stock split to be effected at such time and date, if at all, as determined by the Company’s Board of Directors in its sole discretion. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    25,643,102   1,473,553   591,614   0

    Proposal 3. Ratification of the appointment of the independent registered public accounting firm.

    The Company’s stockholders ratified the appointment by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    26,610,815   485,958   611,496   0


    Proposal 4. Approval of an amendment to the Company’s 2018 Equity Incentive Plan.

    The Company’s stockholders approved the 2018 Amended Plan to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 1,781,000 shares. The final voting results are as follows:

     

    Votes For   Votes Against   Abstentions   Broker Non-Votes
    17,935,157   2,300,322   595,546   6,877,244

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit

    Number

      

    Description

    10.1

      

    Equillium, Inc. 2018 Equity Incentive Plan, as amended.

    104

      

    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

       

    EQUILLIUM, INC.

    Date: May 22, 2025

       

    By:

     

    /s/ Bruce D. Steel

         

    Bruce D. Steel

         

    President and Chief Executive Officer

    Get the next $EQ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EQ

    DatePrice TargetRatingAnalyst
    3/28/2025$3.00 → $1.00Outperform → Market Perform
    Leerink Partners
    1/5/2022$18.00 → $14.00Outperform
    SVB Leerink
    10/29/2021$12.00Buy
    Stifel
    9/15/2021$14.00Overweight
    Cantor Fitzgerald
    More analyst ratings